Biocon and IATRICa to Develop Immunoconjugates against Cancer

Bangalore, Jan 17 (UNI) Biocon Ltd and IATRICa, Inc. today announced a strategic partnership to co-develop an exclusive new class of immunoconjugates for immunotherapy of cancers and infectious diseases.

The companies would co-develop candidate products based upon IATRICa's technology platform and Biocon's proven expertise in drug development, biologics manufacturing, and clinical research, a Biocon press release said.

IATRICa's technology enables development of a diverse spectrum of immunoconjugates that are capable of activating potent targeted immune responses against various tumors or pathogens.

They would leverage and integrate their synergistic R&D expertise to formulate and test next-generation antibody-based immunoconjugates that are more effective than current therapeutic antibodies against cancers and infectious disorders. In addition to a co-development and licensing agreement, Biocon has also made an equity investment in IATRICa.

UNI RM RS TS1625